B Vitamins
B vitamins are essential cofactors for energy metabolism and neurological function.
Energy Profile. Category A (net energy provider). B vitamins are essential cofactors for virtually every step of cellular energy production: thiamine (pyruvate dehydrogenase), riboflavin (Complex I/II), niacin (NAD+ synthesis), pantothenic acid (CoA synthesis), pyridoxine (amino acid metabolism). Deficiency at any point creates an energy production bottleneck. Supplementation removes bottlenecks with negligible processing cost.
1 Thiamine (B1)
Rationale. Essential for pyruvate dehydrogenase (PDH)—the enzyme that feeds pyruvate into the TCA cycle. PDH dysfunction is documented in ME/CFS.
Evidence. Preliminary. Case reports and small studies suggest high-dose thiamine may help a subset of ME/CFS patients. One Italian study used 600–1800 mg daily with significant benefit in chronic fatigue
Forms.
- Thiamine HCl: Standard form; limited absorption
- Benfotiamine: Fat-soluble; better absorbed; doesn’t cross BBB well
- Thiamine TTFD (Allithiamine): Lipid-soluble; crosses BBB; may be most relevant for ME/CFS
Dosing. Standard: 50–100 mg. High-dose protocols: 300–1800 mg daily (under medical supervision).
2 Riboflavin (B2)
Rationale. Precursor to FAD, essential for Complex II (succinate dehydrogenase) and fatty acid oxidation.
Evidence. Theoretical; studied in migraine prevention (400 mg daily).
Dosing. 25–400 mg daily. Harmless neon yellow urine at higher doses.
3 Niacin/Niacinamide (B3)
See NAD+ precursors above.
4 Pyridoxine/P5P (B6)
Rationale. Cofactor for neurotransmitter synthesis (serotonin, dopamine, GABA). The active form pyridoxal-5-phosphate (P5P) is the essential cofactor for aromatic L-amino acid decarboxylase, the enzyme that converts 5-HTP to serotonin. In the enterochromaffin-vagal pathway (Wirth and Scheibenbogen 2025), adequate P5P is therefore required for the final step of gut serotonin synthesis and downstream vagal activation. B6 is water-soluble and may be depleted by chronic inflammation and GI malabsorption—conditions common in ME/CFS; B6 status has not been systematically studied in ME/CFS cohorts.
Dosing. 25–100 mg daily. P5P (pyridoxal-5-phosphate) is the active form and may be better for those with conversion issues. When supporting gut serotonin synthesis (see Section Theanine Glutamate Analog + GABAergic), pair with 5-HTP or tryptophan supplementation.
Cautions. High doses (\(\\>\) 200 mg/day chronically) can cause peripheral neuropathy. Assess RBC P5P levels if possible, as this is a more sensitive marker than serum B6.
Certainty: 0.35. The active form P5P is the essential cofactor for glutamic acid decarboxylase (GAD), the rate-limiting enzyme converting glutamate to GABA. If E/I imbalance involves insufficient GABA synthesis, P5P supplementation could shift the glutamate→GABA balance toward inhibition. P5P 50-100mg/day. No ME/CFS data.
Falsifiable prediction. 8 weeks P5P increases MRS-measured GABA:Glx ratio only in high Glu-PRS subgroup.
5 Folate (B9)
Rationale. Essential for methylation and DNA synthesis.
Forms.
- Folic acid: Synthetic; requires enzymatic conversion via MTHFR; individuals with MTHFR C677T variants have impaired conversion (Zarembska, Ślusarczyk, and Wrzosek 2023)
- Methylfolate (5-MTHF): Active form; bypasses MTHFR; may be preferred in patients with confirmed MTHFR variants
- Folinic acid: Intermediate; doesn’t require MTHFR
Dosing. 400–1000 mcg daily; higher doses (up to 15 mg) used for specific indications.
The MTHFR C677T polymorphism (reducing enzyme activity to 25–67% of normal (Zarembska, Ślusarczyk, and Wrzosek 2023)) impairs conversion of folic acid to the active 5-methyltetrahydrofolate form. In ME/FM patients, folate doses matched to MTHFR genotype were associated with better B12/folate treatment response compared to non-genotype-guided dosing (Regland et al. 2015). For patients with confirmed MTHFR variants, supplementation with the pre-reduced form (methylfolate, 5-MTHF) bypasses the enzymatic bottleneck, though RCT evidence for this approach in ME/CFS is absent.
Cautions. Must be balanced with B12; folate alone can mask B12 deficiency.
5.1 BH4 Recycling Support: Folinic Acid + Vitamin C + Iron
The BH4 convergent bottleneck hypothesis (BH4 Depletion as the Convergent Bottleneck Linking Predisposing Conditions to ME/CFS) identifies tetrahydrobiopterin depletion as a potential convergence point for multiple ME/CFS predisposing conditions. Direct BH4 supplementation (sapropterin) is expensive and requires prescription (LOX-Mediated Collagen Stabilization). A combination of cofactors supporting endogenous BH4 recycling may achieve partial benefit at much lower cost:
- Folinic acid (5-MTHF), 400–800 mcg: Supports dihydrofolate reductase (DHFR)-mediated BH4 regeneration from BH2. Preferred over folic acid because it bypasses MTHFR polymorphisms common in neurodivergent populations. Contraindicated in patients on methotrexate (used in co-occurring autoimmune conditions) — folinic acid antagonises methotrexate’s therapeutic effect. Consult prescriber before initiating.
- Vitamin C, 500–1000 mg: Prevents BH4 oxidation to BH2 by scavenging peroxynitrite. Also serves as dopamine beta-hydroxylase cofactor (norepinephrine synthesis).
- Iron bisglycinate: Cofactor for dihydropteridine reductase (DHPR), the enzyme that recycles BH4. Dose titrated to ferritin \(> 100\) ng/mL per Architecture C rationale (LOX-Mediated Collagen Stabilization).
This combination supports endogenous BH4 recycling rather than providing exogenous BH4. Effectiveness depends on residual GCH1 activity — it will not help severe GCH1 deficiency (homozygous loss-of-function variants). No clinical data exist for this specific combination in any condition. The rationale is biochemically logical but entirely untested.
If the OTC combination produces no improvement in urinary neopterin:biopterin ratio after 8 weeks of adherence, and the patient is confirmed GCH1 rs841 homozygous, escalation to sapropterin should be discussed with a metabolic specialist — this is the point at which endogenous recycling support has failed and exogenous BH4 may be required.
Certainty: 0.25. If the BH4 convergent bottleneck hypothesis is correct, a combination of folinic acid, vitamin C, and iron supporting BH4 recycling should produce measurable improvement in urinary neopterin:biopterin ratio and correlated symptom improvement (cognition, orthostatic tolerance) in ME/CFS patients with elevated neopterin:biopterin at baseline. This is testable with a pre/post design measuring the biomarker before and after 8 weeks of supplementation. All components are OTC, well-tolerated, and cheap (~$20/month combined). Biochemically logical; no clinical data for this combination. Not yet replicated.
6 Cobalamin (B12)
Rationale. Essential for methylation, nerve function, and energy metabolism.
Evidence. Low–Moderate. Some ME/CFS patients respond dramatically to B12, especially sublingual or injectable forms; others show no benefit. In a large patient-reported survey (\(n = 3{,}925\)), B12 injections (47.1% positive response) significantly outperformed oral B12 (30.5%) (Eckey et al. 2025) — the largest-scale format-comparison signal and consistent with the mechanistic rationale that parenteral administration bypasses absorption limitations and drives tissue B12/MMA changes more reliably. (Severity applicability: unknown — survey did not stratify by severity.)
Forms.
- Cyanocobalamin: Cheapest; requires conversion; contains cyanide moiety (trivial amount)
- Methylcobalamin: Active methylated form; supports methylation
- Adenosylcobalamin: Active form used in mitochondria
- Hydroxocobalamin: Well-retained; often used in injections
Dosing. Oral: 1000–5000 mcg sublingual daily. Injections: 1000 mcg weekly to monthly (requires prescription in most countries).
Note on Testing. Serum B12 is a poor marker of tissue status. Methylmalonic acid (MMA) and homocysteine are more sensitive.
Clinical evidence for B12 supplementation in ME/CFS comes from small open-label studies only. Regland et al. found that among 38 ME/FM patients receiving B12 injections, good responders used higher doses and more frequent injections, and had folic acid doses matched to their MTHFR genotype (Regland et al. 2015). Van Campen et al. found that intranasal hydroxocobalamin improved physical activity in 34/51 ME/CFS patients (67%) over 3 months Campen, Riepma, and Visser (2019).
Neither study included a placebo control group. Placebo-controlled RCT evidence is absent. These findings should inform patient-physician discussions and hypothesis-driven trials, but cannot be used to establish B12/folate supplementation as an evidence-based treatment for ME/CFS. Patient response appears heterogeneous (33% non-responders in van Campen 2019), suggesting that subgroup stratification (e.g., by MTHFR genotype, baseline CSF homocysteine) is needed before this approach can be recommended broadly.
(Certainty: 0.40 — three independently supported mechanistic steps: MTHFR impairment → H3K9me3 loss → pericentromeric derepression; methylation loss → repeat expression (ICF syndrome Mendelian proof); HSAT2 → immune suppression; no direct ME/CFS HSAT2 methylation data.)
Pericentromeric satellite repeats including HSAT2 are epigenetically silenced in healthy somatic cells primarily through H3K9 trimethylation (via SUV39H1/2, SETDB1), with CpG methylation acting as a secondary downstream stabilizer Hypomethylation — caused by methyl-donor depletion (low SAMe/SAH ratio, B12 deficiency, MTHFR variants), viral epigenetic disruption, or inflammatory methylation erosion — permits HSAT2 derepression. ME/CFS shows widespread DNA methylation alterations in peripheral blood (multiple cohort studies), including hypomethylation of repeat-proximal loci. If pericentromeric loci are among the hypomethylated regions, HSAT2 could be chronically derepressed without active viral infection.
Three independent mechanistic pillars now support this pathway:
- MTHFR impairment → pericentromeric derepression: Zhu et al. demonstrated in human cells that MTHFR knockdown reduces H3K9me3 marks at centromeric and pericentromeric loci, permitting satellite repeat transcription. MTHFR variants (C677T) are prevalent in the general population and reduce folate-cycle efficiency.
- Methylation loss → satellite expression (Mendelian proof): ICF syndrome (DNMT3B mutations, an immune deficiency) is caused by satellite II/III hypomethylation and is characterized by satellite repeat expression plus immune deficiency This establishes the causal link between CpG methylation loss at pericentromeric loci and immune pathology.
- Folate-cycle biology in ME/CFS: ME/CFS patients commonly show elevated homocysteine, reduced methyl-donor levels, and sometimes MTHFR variants, consistent with impaired SAM/SAH ratio and reduced DNMT substrate availability.
Methyl-donor supplementation (methylcobalamin, methylfolate, SAMe, choline, betaine) restores the SAM pool required for DNMT-mediated re-methylation. Long-term methyl-donor supplementation (folic acid 400 μg/day + B12 500 μg/day over 2 years) produces measurable genome-wide methylation changes in humans — effect sizes modest and locus-specific, but proof-of-principle that dietary methyl-donor intake can affect the methylation landscape in vivo (Kok et al. 2015). Mechanistic rationale: SAMe is the universal methyl donor for all DNMTs; methyl-folate and methyl-B12 bypass MTHFR polymorphisms and supply one-carbon units; betaine provides an alternative methyl donor via the BHMT pathway (Crider et al. 2012). In patients with documented methyl-donor depletion (low SAMe/SAH, elevated homocysteine, MTHFR variants), targeted supplementation could in principle re-silence HSAT2 loci and reduce the exosomal immunosuppressive burden.
This provides a second, epigenetically-grounded rationale for B12/folate supplementation in ME/CFS beyond the neurological and metabolic justifications already described.
Falsifiable prediction: ME/CFS patients with low SAMe/SAH ratio will show higher exosomal HSAT2 than patients with normal methylation status. Twelve weeks of combined methylcobalamin (1 mg/day sublingual) + methylfolate (1 mg/day) + SAMe (400 mg/day) will reduce exosomal HSAT2 content and improve SAMe/SAH ratio with correlated effect sizes. If HSAT2 is unchanged despite SAMe/SAH normalization, methylation-dependent re-silencing is not operative for these loci.
Limitations: HSAT2 methylation at pericentromeric loci has not been measured in ME/CFS. The Zhu 2014 MTHFR data used extreme siRNA knockdown — whether partial dietary or genetic depletion reaches the threshold for H3K9me3 loss at pericentromeric loci is untested. SAMe supplementation has a complex pharmacology (oral bioavailability ~5%; form stability varies). Pericentromeric heterochromatin silencing requires H3K9me3 to be re-established before DNA methylation can lock in the silenced state — methyl-donor supplementation acts on DNA methylation only, not histone methylation. Not replicated. This rationale is complementary to — not a replacement for — the neurological/metabolic rationale for B12/folate, which has independent evidence.
Mechanistic caveat: Pericentromeric heterochromatin silencing is primarily mediated by histone H3K9 trimethylation (via SUV39H1/2 and SETDB1), not solely by DNA CpG methylation. DNA methylation is a secondary stabilizer of silencing that acts downstream of H3K9me3 establishment. Targeted H3K9me3 restoration (via SUV39H1/SETDB1 modulators) would be a more mechanistically aligned strategy, but no clinical-stage candidates exist.
7 HSAT2-Axis Combination Hypotheses
No clinical trial data exist for any of these combinations in ME/CFS. Do not present these as treatment protocols. Each component’s individual safety profile must be assessed before any combination trial.]
(Certainty: 0.22 — individual components have partial mechanistic support:nr-nmn-hsat2:spermidine-hsat2:hsat2-pem-amplification; combination synergy untested.)
The SIRT1/NAD+-axis hypothesis:sirt1-hsat2-upstream proposes that NAD+ depletion leads to SIRT1 inactivation → SUV39H1 instability → H3K9me3 loss → HSAT2 derepression. Three interventions address distinct nodes of this axis: (1) NR/NMN restores the NAD+ substrate for SIRT1:nr-nmn-hsat2; (2) spermidine supports autophagy and heterochromatin maintenance:spermidine-hsat2; (3) strict pacing prevents the exertional HSF1-HSAT2 induction events that would overwhelm any epigenetic silencing support:hsat2-pem-amplification. Each alone is predicted to produce modest effects; together they address different points of failure in the silencing maintenance chain.
The combination is mechanistically non-redundant: NR addresses substrate supply; spermidine addresses proteostasis and chromatin maintenance capacity; pacing addresses the epigenetic insult rate. Synergy between NR and spermidine for heterochromatin maintenance has been proposed (but not demonstrated) in aging biology. Pacing provides the “reduction in demand” that makes any restoration effort more effective.
Access (Belgium/EU): NR (Niagen, Tru Niagen): OTC supplement, approximately €60–80/month. Spermidine: OTC supplement, approximately €15–30/month. Pacing: requires only a heart-rate monitor (~€60 one-time) and patient education. Total running cost approximately €75–110/month. No INAMI/RIZIV reimbursement for any component.
Falsifiable prediction: NR + spermidine + pacing x 12 weeks will reduce plasma EV HSAT2 by \(\geq 30%\); either NR alone or spermidine alone will reduce EV HSAT2 by \(\leq 15%\) (synergy test). Pacing alone will reduce the rate of EV HSAT2 fluctuation but not the baseline level.
Limitations: No combination trial data. The synergy assumption is biological plausibility only. Spermidine-SAMe competition could blunt methyl-donor support if co-administered with @spec-methyl-donor-hsat2. The combination addresses epigenetic silencing upstream but does not directly target MDSC expansion or NK cytotoxicity. Not replicated.
(Certainty: 0.28 — each component has separate mechanistic support:tadalafil-mdsc-nk:citrulline-nk-mdsc; bidirectional combination untested in any context.)
The MDSC→NK suppression arm of the HSAT2 loop operates through arginase-1-mediated L-arginine depletion Two interventions address this at different points: tadalafil (PDE5 inhibitor) depletes MDSC arginase-1 expression and promotes MDSC differentiation into mature myeloid cells:tadalafil-mdsc-nk; L-citrulline replenishes the substrate arginine pool that MDSC arginase-1 has depleted:citrulline-nk-mdsc. The combination targets both the enzyme and the substrate simultaneously — a mechanistically complementary pairing.
Neither intervention alone is predicted to produce \(> 15%\) NK cytotoxicity improvement (one addresses supply, the other demand); together they should produce \(\geq 30%\) improvement (the combination prediction is based on independence of mechanisms, not synergy in the strict pharmacological sense).
Access (Belgium/EU): Tadalafil 5 mg generic: approximately €20–40/month off-label (not reimbursed by INAMI/RIZIV for ME/CFS; requires GP/specialist willing to prescribe off-label — confirm this is acceptable and document informed consent). L-citrulline: OTC supplement, approximately €15–25/month. Total approximately €35–65/month.
Falsifiable prediction: Tadalafil 5 mg/day + L-citrulline 6 g/day x 8 weeks will increase NK cytotoxicity (CD107a flow, K562 target) by \(\geq 30%\) and reduce plasma arginase-1 activity by \(\geq 25%\); either alone will produce \(\leq 15%\) NK improvement.
Limitations: Tadalafil is off-label in ME/CFS. Hypotension risk is relevant in POTS/OI patients; blood pressure monitoring required. MDSC data in ME/CFS are absent — the combination assumes the arginase-1 mechanism is operative. L-citrulline alone at 6 g/day may cause mild GI symptoms (dose-titration recommended). Not replicated in ME/CFS or any chronic post-viral setting.
(Certainty: 0.30 within the TT stratum — MTHFR C677T homozygous genotype is well-established as a risk factor for reduced H3K9me3 at pericentromeric loci; response stratification by genotype is biologically motivated but not yet demonstrated.)
The methyl-donor hypothesis:methyl-donor-hsat2 is heterogeneous: patients with the MTHFR C677T homozygous TT genotype (approximately 10–15% of European populations, including Belgian) have approximately 30–70% reduced MTHFR enzyme activity, reduced plasma folate, and reduced SAMe/SAH ratio — the exact methylation-deficient state that showed leads to H3K9me3 loss at pericentromeric loci. For TT patients, targeted methyl-donor supplementation addresses a documented biochemical deficit that is directly in the predicted HSAT2 derepression pathway.
CC and CT genotype patients do not have the same MTHFR-driven methylation deficit; methyl-donor supplementation in these patients would be addressing a non-existent gap and is not predicted to reduce EV HSAT2. Combining genotype stratification with the methyl-donor intervention therefore both improves the predicted effect size in responders and avoids unnecessary supplementation in non-responders.
The combination: SAMe 400 mg/day (morning, fasted) + methylfolate 1 mg/day + methylcobalamin 1 mg/day (sublingual). MTHFR C677T genotyping is available commercially (approximately €80–150 private; not reimbursed by mutualité for ME/CFS indication in Belgium). SAMe and folate are OTC; B12 hydroxocobalamin is available IM via GP. Total running cost approximately €30–50/month after genotyping.
Falsifiable prediction: In a MTHFR-stratified trial, TT-genotype ME/CFS patients will show \(\geq 20%\) EV HSAT2 reduction at 12 weeks; CC-genotype patients will show \(< 10%\) change. If TT patients do not respond, the MTHFR→methylation→H3K9me3→HSAT2 chain is not operative despite the genetic risk factor.
Limitations: MTHFR genotyping is a practical barrier. SAMe oral bioavailability is approximately 5%; enteric-coated preparations improve this but quality varies. The Zhu 2014 data used extreme siRNA knockdown of MTHFR — partial genetic depletion (TT genotype) may not reach the threshold for H3K9me3 loss at pericentromeric loci. This rationale is additive to — not a replacement for — the neurological B12/folate rationale in ME/CFS. Not replicated.